Fenofibrate in Ulcerative Colitis
Clinical Study to Evaluate the Possible Efficacy of Fenofibrate in Patient With Ulcerative Colitis
Tanta University
60 participants
Feb 28, 2023
INTERVENTIONAL
Conditions
Summary
Fibrates, which are specific pharmacological agonists of PPARα, have been widely used in the treatment of hypercholesterolemia and hypertriglyceridemia. Apart from their metabolic action, anti-inflammatory properties of fibrates have been described, including inhibition of NF-kappa B signaling and pro-inflammatory cytokine production. 4 Fenofibrate, an important peroxisome proliferator-activated receptor-a (PPAR- α) agonist, is widely used in clinical as a triglyceride (TG)-lowering agent.
Eligibility
Inclusion Criteria4
- Age ≥ 18 years
- Both males and females will be included
- Negative pregnancy test and effective contraception.
- Mild and moderate UC patients diagnosed and confirmed by an endoscope
Exclusion Criteria9
- Breastfeeding
- Significant liver and kidney function abnormalities
- Colorectal cancer patients
- Other inflammatory bowel diseases (CD).
- Patients with severe UC
- Patients taking rectal or systemic steroids
- Patients taking immunosuppressives or biological therapies
- Addiction to alcohol and/or drugs
- Known allergy to the Fenofibrate
Interventions
Mesalamine (also known as mesalamine or 5- amino salicylic acid, 5-ASA) has a well-established role in UC management. It is the first line therapy for mild to moderate UC and it is considered the cornerstone in the management of UC
Fibrates, which are specific pharmacological agonists of PPARα, have been widely used in the treatment of hypercholesterolemia and hypertriglyceridemia.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05753267